Literature DB >> 29129445

Bevacizumab in adjuvant treatment of non-small-cell lung cancer.

Jared Weiss1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29129445     DOI： 10.1016/S1470-2045(17)30843-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.

Authors:  Ya-Nan Liu; Jie Huang; Can Guo; Shuang Yang; Ling Ye; Shu-Ting Wu; Xing-Fei Zhang; Xiao-Yan Yang; Cui-Cui Han; Qi Pei; Lu Huang; Qing-Nan He; Guo-Ping Yang
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-06       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.